慢性抗血栓治疗患者全膝关节置换术结局的系统综述
该系统综述纳入17项回顾性比较研究,共104,182例接受慢性抗血栓治疗的患者和261,139例对照,分析全膝关节置换术后的围手术期及远期结局。华法林与更多失血、更高输血率和更长住院时间相关,抗血小板治疗未显示一致的围手术期不良影响,直接口服抗凝药与较低的假体周围感染和伤口裂开率相关。结论认为在适当围手术期管理下全膝关节置换术可行,但华法林患者需更密切监测。
要点
- 华法林与更多失血、更高输血率、更长住院时间及更高伤口并发症风险相关。
- 抗血小板治疗未显示一致的围手术期不良影响。
- 直接口服抗凝药与较低的假体周围感染和伤口裂开率相关。
核心结论
- 华法林与更多失血、更长住院时间及更高伤口并发症、心肌梗死和肺栓塞风险相关,其他结局无差异或不确定。
- 在适当围手术期管理下,慢性抗血栓治疗患者行全膝关节置换术可行,但华法林患者需更密切监测。
研究设计与样本
- 系统综述纳入17项回顾性比较研究,共104,182例接受慢性抗血栓治疗的患者和261,139例对照。
- 文献检索截至2025年10月,纳入报告长期抗血栓治疗患者初次全膝关节置换术结局的研究。
主要发现
- 华法林与更多失血、更高输血率和更长住院时间相关。
- 抗血小板治疗未显示一致的围手术期不良影响。
- 直接口服抗凝药与较低的假体周围感染和伤口裂开率相关。
- 血栓栓塞、感染、伤口和翻修结局的报告存在异质性。
关键数值与推荐
- 抗血栓方案分为抗血小板治疗、华法林、直接口服抗凝药或混合方案,混合方案未按抗凝药类别分别报告结局。
- 结局指标包括围手术期参数、内科并发症、血栓栓塞事件和远期结局,采用描述性综合。
临床怎么用
- 慢性抗血栓治疗患者行全膝关节置换术时,华法林患者需更密切监测围手术期失血、输血和伤口并发症。
- 抗血小板治疗患者未显示一致的围手术期不良影响,直接口服抗凝药可能与较低的假体周围感染和伤口裂开率相关。
局限性
- 纳入研究均为回顾性比较研究,结局报告存在异质性。
- 混合抗血栓方案未按抗凝药类别分别报告结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With population aging and increasing cardiovascular comorbidity, more patients undergoing total knee arthroplasty (TKA) require chronic antithrombotic therapy. The impact of long-term anticoagulant or antiplatelet use on perioperative and longer-term outcomes after TKA remains unclear. This systematic review summarizes postoperative outcomes in patients receiving chronic antithrombotic therapy, examines differences by antithrombotic class, and compares outcomes with nonanticoagulated controls. METHODS: A systematic literature search was conducted through October 2025. There were 17 retrospective comparative studies, including 104,182 patients receiving chronic antithrombotic therapy and 261,139 controls, which were analyzed. Studies reporting outcomes of primary TKA in patients receiving long-term antithrombotic therapy were included. Extracted outcomes comprised perioperative parameters, medical complications, thromboembolic events, and longer-term outcomes. Antithrombotic regimens were categorized as antiplatelet therapy, warfarin, direct oral anticoagulants or mixed regimen (outcomes were not reported separately by anticoagulant class in this group), and findings were synthesized descriptively. RESULTS: Warfarin use was associated with greater blood loss, higher transfusion rates, and longer hospitalization, whereas antiplatelet therapy showed no consistent adverse perioperative effects. Direct oral anticoagulant therapy was related to lower rates of periprosthetic joint infection and wound dehiscence. Reporting of thromboembolic, infectious, wound, and revision outcomes was heterogeneous. CONCLUSION: Warfarin use in TKA, compared with antiplatelet and direct oral anticoagulant therapy, is associated with greater blood loss, longer hospitalization, and higher risk of wound complications, myocardial infarction, and pulmonary embolism, while other outcomes show no difference or remain inconclusive. Despite this, TKA is feasible under chronic antithrombotic therapy with proper perioperative management, though warfarin patients require closer monitoring and further research is needed.
引用
- Vosoughi F, Ramezanpour MR, Hashemi FS, et al. Outcomes of Total Knee Arthroplasty in Patients Receiving Chronic Antithrombotic Therapy: A Systematic Review. J Arthroplasty. 2026. PMID: 42546786. doi:10.1016/j.arth.2026.07.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。